Moise Desvarieux, MD, PhD, MPH

Dr Desvarieux is a multi-morbidity epidemiologist straddling the fields of chronic and infectious disease. Over the past 25 years, he has had substantial experience in population health, in follow-up of hard-to-reach populations as well as coordinating analysis of large multi-center datasets. He started his career as an Epidemiologist for the Cornell University Infectious Diseases Research Unit in Haiti, mostly focused on HIV and tuberculosis. At Columbia, he was the co-Principal Investigator of a CDC-funded grant evaluating the impact of the initiation of directly observed therapy for tuberculosis for the 209 US cities over 100,000 inhabitants over a 15-year period.  Building on his infectious disease vantage point, he then straddled the field of chronic disease as PI of the NIH-funded INVEST cohort investigating the contribution of periodontal microbiota and low-grade inflammation to cardiovascular disease risk, since its inception in 2000. He contributed significantly to this line of research in the US as well as internationally as Principal Investigator of the NIH- funded planning grant on Oral Infections and Vascular Risk in Seven Countries. He has been the recipient of a Chair of Excellence by the French Institut National de la Sante et de la Recherche Medicale, INSERM to conduct comparative studies on chronic infections/inflammation and vascular disease internationally, and as such, he served as PI of the INNOVATE consortium (International Network on Oral and Vascular Disease in Transatlantic and European cohorts).  He logically extended his research, collaboratively, to other chronic conditions such as neurological disease and diabetes, as well as to investigation of the contribution of HIV-related inflammatory imbalance to the increased vascular risk.  More recently, Dr. Desvarieux was asked to be the PI of the EURECCCA Real-World Evidence consortium originally covering 13 countries and coalescing electronic health records  (EHR) and real-world data (RWD) data-sources, clinical, private, public and research platforms, enabling collaboration and communication using understandable language, harmonizing and investigating differences and similarities to determine nodes of intervention for improvement in care/health policy. The goal is to advance management of complex chronic conditions, contribute to personalized health, provide both practical predictive algorithms and a platform for emulated trials for multimorbidity, reflecting the complexity of patients' lives. He co-directs (with Philippe Ravaud) the Columbia-INSERM International Associated Laboratory on Chronic Disease, with Fellows dedicated to research on methodology aimed at harnessing of RWD for public health, including recently long COVID. Dr. Desvarieux has a track-record of successfully engaging in large collaborative groups from diverse backgrounds, addressing questions of import for public health.